Please type a plus sign (+) inside this box

PTO/SB/05 (03-01) Approved for use through 10/31/2002, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION

REG 195-BZ Attorney Docket No. David M. Valenzuela First Inventor Novel Tyrosine Kinase Receptors and Ligands

TRANSMITTAL Express Mail Label No. ET712522480US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) 1. LX CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission 2 See 37 CFR 1.27. (if applicable, all necessary) Pecinication [Total Pages elemed errangement set forth below) Specification 3 X Computer Readable Form (CRF) Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications i. CD-ROM or CD-R (2 copies); or Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, i i. 🔲 paper or a computer program listing appendix - Background of the Invention Statements verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attomev English Translation Document (if applicable) 4. X Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 5. Oath or Declaration [Total Pages Citations Statement (IDS)/PTO-1449 13. X *Preliminary Amendment Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. X Other Associate Power of Attorney 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation X · Divisional 09 077.955 Continuation-in-part (CIP) of prior application No.: $_{\textit{Examiner}}\underline{R}$. Landsman Prior application information: 1647 Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS N. FORWALL X . Correspondence address below Customer Number or Bar Code Label (Insert Customer, No. or Attach ber code label here) Name Linda O. Palladino Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road **Address** City Tarrytown State New York Zip Code 10591 Fax Country United States 914-345-7400 Telephone 914-345-77**1**1 Name (Print/Type) Linda 0. Pallading Registration No. (Attorney/Agent) 45,636 Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.





PTO/SB/05 (03-01)
Please type a plus sign (+) inside this box

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 16-35, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

Attorney Docket No. REG 195-BZ David M. Valenzuela First Inventor Novel Tyrosine Kinase Receptors and Ligands

(Only for new nonprovision	nal applications under 37 CFR 1.53(b))	Express Mail Label No. ET712522480US
APPLICATION ELEMENTS		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application
See MPEP chapter 600 concerning utility patent application contents.		Washington, DC 20231
1. X Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. 3. X Specification [Total Pages 96,] (preferred arrangement set forth below) - Descriptive title of the invention		 CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Computer Readable Form (CRF) Specification Sequence Listing on:
- Statement Reg - Reference to se or a computer p - Background of - Brief Summary	of the Invention in of the Drawings (if filed) ption	i. CD-ROM or CD-R (2 copies); or i i. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 37 CFR 3.73(b) Statement (when there is an assignee) Attorney
4. X Drawing(s) (35 U	I.S.C. 113) [Total Sheets 24]	11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449
a. Newly executed (original or copy) Copy from a prior application (37 CFR 1 63 (d))		13. X Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)		15. (Sribula be specifically territzed) 15. (if foreign priority is claimed)
named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
6. Application Data Sheet. See 37 CFR 1.76		17. X Other: Associate Power of Attorney
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation		
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS		
Customer Number or Ber Code Label (Insert Customer, Nonor, Attach bar code label, here) or X . Correspondence address below		
Name	Linda O. Palladino	
Address	Regeneron Pharmace 777 Old Saw Mill R	
City	Tarrytown	State New York Zip Code 10591
Country		phone 914-345-7400 Fax 914-345-7721
Name (PrintlType)	Linda O. Palladino	Registration No. (Attorney/Agent) 45,636
Signature	KINDO. POL	ladino Date 11/30/01
Burden Hour Statement: This form	in actimated to take 0.2 hours to complete. Time	will consider and the condition of the ball the state of the same

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application. Washington, DC 20231.

